Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia

Schizophrenia Research

Volumn 111, Issue 1-3, 2009, Pages 131-137

  Ghose, Subroto ^a   Chin, Ronald ^a   Gallegos, Analysa ^a   Roberts, Rosalinda ^b   Coyle, Joseph ^c   Tamminga, Carol ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Glutamate; GRM3; In situ; mGluR3; Post mortem; Psychosis

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; MESSENGER RNA; METABOTROPIC RECEPTOR 3; N ACETYLASPARTYLGLUTAMIC ACID;

ARTICLE; DENTATE GYRUS; GENE EXPRESSION; GENE LOCATION; HIPPOCAMPUS; HUMAN; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, SURFACE; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER; SCHIZOPHRENIA; YOUNG ADULT;

EID: 67349118380     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.03.038     Document Type: Article

References (50)

1. Ansausti R., and Amaral D. Hippocampal Formation in the Human Nervous System (2004), Elsevier, San Diego, CA
2. Baslow M.H., Dyakin V.V., Nowak K.L., Hungund B.L., and Guilfoyle D.N. 2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia. Journal of Molecular Neuroscience 26 (2005) 1-15
3. Berger U.V., Luthi-Carter R., Passani L.A., Elkabes S., Black I., Konradi C., et al. Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. The Journal of comparative neurology 415 (1999) 52-64
4. Bergeron R., Coyle J.T., Tsai G., and Greene R.W. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 30 (2005) 7-16
5. Bergeron R., Imamura Y., Frangioni J.V., Greene R.W., and Coyle J.T. Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. Journal of neurochemistry 100 (2007) 346-357
6. Coyle J.T. The nagging question of the function of N-acetylaspartylglutamate. Neurobiology of Disease 4 (1997) 231-238
7. Eichenbaum H. A cortical-hippocampal system for declarative memory. Nature Reviews. Neuroscience 1 (2000) 41-50
8. Flores C., and Coyle J.T. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology 28 (2003) 1227-1234
9. Fotuhi M., Standaert D.G., Testa C.M., Penney Jr. J.B., and Young A.B. Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the rat. Brain Research 21 (1994) 283-292
10. Frickler A.C., Selina Mok M.H., de la Flor R., Shah A.J., Woolley M., Dawson L.A., and Kew J.N. Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 12 (2009) Mar, [Electronic publication]
11. Ghose S., Weickert C.S., Colvin S.M., Coyle J.T., Herman M.M., Hyde T.M., et al. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 29 (2004) 117-125
12. Ghose S., Crook J.M., Bartus C.L., Sherman T.G., Herman M.M., Hyde T.M., et al. Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. International Journal of Neurosci 118 (2008) 1609-1627
13. Ghose, S., Gleason, K., Potts, B., Lewis-Amezcua, K., Tamminga, C., in press. Differential expression of metabotropic glutamate receptor 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? American Journal of Psychiatry.
14. Guilarte T.R., Hammoud D.A., McGlothan J.L., Caffo B.S., Foss C.A., Kozikowski A.P., et al. Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophrenia Research 99 (2008) 324-332
15. Hess S., Pasieczny R., Rao S., Jachec C., Varney M., and Johnson E. Activity of N-cetylaspartylglutamate at human recombinant glutamate receptors. 29th Annual Meeting (1999), Society for Neuroscience, Miami Beach, FL 975
16. Lavenex P., and Amaral D.G. Hippocampal-neocortical interaction: a hierarchy of associativity. Hippocampus 10 (2000) 420-430
17. Losi G., Vicini S., and Neale J. NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. Neuropharmacology 46 (2004) 490-496
18. Lyon L., Kew J.N., Corti C., Harrison P.J., and Burnet P.W. Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse (New York, NY 62 (2008) 842-850
19. Medoff D.R., Holcomb H.H., Lahti A.C., and Tamminga C.A. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11 (2001) 543-550
20. Moser M.B., and Moser E.I. Functional differentiation in the hippocampus. Hippocampus 8 (1998) 608-619
21. Neale J.H., Bzdega T., and Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. Journal of neurochemistry 75 (2000) 443-452
22. Ohishi H., Shigemoto R., Nakanishi S., and Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. The Journal of comparative neurology 335 (1993) 252-266
23. Pegues M.P., Rogers L.J., Amend D., Vinogradov S., and Deicken R.F. Anterior hippocampal volume reduction in male patients with schizophrenia. Schizophrenia research 60 (2003) 105-115
24. Sanabria E.R., Wozniak K.M., Slusher B.S., and Keller A. GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. Journal of Neurophysiology 91 (2004) 182-193
25. Sekiguchi M., Okamoto K., and Sakai Y. Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Research 482 (1989) 87-96
26. Shenton M.E., Kikinis R., Jolesz F.A., Pollak S.D., LeMay M., Wible C.G., et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. The New England journal of medicine 327 (1992) 604-612
27. Slusher B.S., Vornov J.J., Thomas A.G., Hurn P.D., Harukuni I., Bhardwaj A., et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Natural Medicines 5 (1999) 1396-1402
28. Stan A., Ghose A., Lewis-Amezcua K., Roberts R., Gao X.M., and Tamminga C.A. Human postmortem tissue: what quality markers matter?. Brain Res. 1123 (2006) 1-11
29. Stauch B.L., Robinson M.B., Forloni G., Tsai G., and Coyle J.T. The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. Neuroscience Letters 100 (1989) 295-300
30. Suddath R.L., Christison G.W., Torrey E.F., Casanova M.F., and Weinberger D.R. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. The New England journal of medicine 322 (1990) 789-794
31. Suzuki W.A., and Amaral D.G. Perirhinal and parahippocampal cortices of the macaque monkey: cortical afferents. Journal of Comparative Neurology 350 (1994) 497-533
32. Suzuki W.A., and Amaral D.G. Topographic organization of the reciprocal connections between the monkey entorhinal cortex and the perirhinal and parahippocampal cortices. Journal of Neuroscience 14 (1994) 1856-1877
33. Sweatt J. Mechanisms of Memory (2003)
34. Sweatt J.D. Hippocampal function in cognition. Psychopharmacology (Berl) 174 (2004) 99-110
35. Szeszko P.R., Goldberg E., Gunduz-Bruce H., Ashtari M., Robinson D., Malhotra A.K., et al. Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. The American journal of psychiatry 160 (2003) 2190-2197
36. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Archives of general psychiatry 49 (1992) 522-530
37. Tamminga C.A., Vogel M., Gao X., Lahti A.C., and Holcomb H.H. The limbic cortex in schizophrenia: focus on the anterior cingulate. Brain Research. Brain Research Reviews 31 (2000) 364-370
38. Tamminga C.A., Lahti A.C., Medoff D.R., Gao X.M., and Holcomb H.H. Evaluating glutamatergic transmission in schizophrenia. Annals of the New York Academy of Sciences 1003 (2003) 113-118
39. Tanabe Y., Nomura A., Masu M., Shigemoto R., Mizuno N., and Nakanishi S. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. Journal of Neuroscience 13 (1993) 1372-1378
40. Testa C.M., Standaert D.G., Young A.B., and Penney Jr. J.B. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. Journal of Neuroscience 14 (1994) 3005-3018
41. Tranel D., Brady D.R., Van Hoesen G.W., and Damasio A.R. Parahippocampal projections to posterior auditory association cortex (area Tpt) in Old-World monkeys. Experimental Brain Research 70 (1988) 406-416
42. Trombley P.Q., and Westbrook G.L. Excitatory synaptic transmission in cultures of rat olfactory bulb. Journal of Neurophysiology 64 (1990) 598-606
43. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archives of General Psychiatry 52 (1995) 829-836
44. Weinberger D.R., Berman K.F., Suddath R., and Torrey E.F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. American Journal of Psychiatry 149 (1992) 890-897
45. Weinberger D.R., Berman K.F., and Torrey E.F. Correlations between abnormal hippocampal morphology and prefrontal physiology in schizophrenia. Clinical Neuropharmacology 15 Suppl 1 (1992) 393A-394A Pt A
46. Westbrook G.L., Mayer M.L., Namboodiri M.A., and Neale J.H. High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. Journal of Neuroscience 6 (1986) 3385-3392
47. Witter M.P., Wouterlood F.G., Naber P.A., and Van Haeften T. Anatomical organization of the parahippocampal-hippocampal network. Annals of the New York Academy of Sciences 911 (2000) 1-24
48. Wroblewska B., Wroblewski J.T., Pshenichkin S., Surin A., Sullivan S.E., and Neale J.H. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. Journal of Neurochemistry 69 (1997) 174-181
49. Wroblewska B., Santi M.R., and Neale J.H. N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 24 (1998) 172-179
50. Zhong C., Zhao X., Van K.C., Bzdega T., Smyth A., Zhou J., et al. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. Journal of Neurochemistry 97 (2006) 1015-1025